# US 2014/0193836 A1 · Novel markers for dopaminergic neuron progenitor cells > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193836 A1 - Document ID: US20140193836A1 - Status: Published application - Kind: A1 - Application number: 14/234,361 - Filed: 2012-07-27 - Published: 2014-07-10 - Earliest claimed: 2011-07-27 - Assignees: Eisai R&D Management Co., Ltd.; Kyoto University - Inventors: Jun Takahashi; Daisuke Doi; Bumpei Samata; Yuichi Ono - Web page: https://patentgrep.com/patent/US20140193836A1 ## CPC - G01N 33/56966: {Animal cells} - A61P 25/16: Anti-Parkinson drugs - C12N 5/0619: {Neurons} - C12N 5/0623: {Stem cells} - C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor - C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance - C12N 2501/727: Kinases (EC 2.7.) - C12N 2502/1394: Bone marrow stromal cells; whole marrow - C12N 2506/02: from embryonic cells - C12N 2506/45: from artificially induced pluripotent stem cells - C12N 2509/00: Methods for the dissociation of cells, e.g. specific use of enzymes - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Cc17, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3ga16, Slc39a12, Tacr1, Lrtm1, Dscam and CD201. ## Claims ### Claim 1 A method for producing dopaminergic neuron progenitor cells, said method comprising: extracting dopaminergic neuron progenitor cells from a cell population comprising dopaminergic neuron progenitor cells by using as an index/indices the positivity/positivities of any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Ccl7, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3ga16, Slc39a12, Tacr1, Lrtm1 and Dscam, and/or the negativity of CD201. ### Claim 2 (depends on 1) The method according to claim 1, wherein the positive marker is Lrtm1. ### Claim 3 (depends on 1) The method according to claim 1, wherein said step further comprises extracting dopaminergic neuron progenitor cells by using as an index/indices the positivity/positivities of corin and/or Lmx1a. ### Claim 4 (depends on 1) The method according to claim 1, wherein said dopaminergic neuron progenitor cells are human dopaminergic neuron progenitor cells. ### Claim 5 (depends on 1) The method according to claim 1, wherein said cell population comprising dopaminergic neuron progenitor cells is a cell population whose differentiation is induced from pluripotent stem cells, or a cell population composed of cells of an isolated tissue(s). ### Claim 6 (depends on 5) The method according to claim 5, wherein said cell population whose differentiation is induced from pluripotent stem cells is a cell population obtained by culturing pluripotent stem cells in a medium supplemented with a BMP inhibitor and a TGFβ inhibitor. ### Claim 7 A method for detecting dopaminergic neuron progenitor cells in a cell population comprising dopaminergic neuron progenitor cells, said method comprising detecting dopaminergic neuron progenitor cells using as an index/indices the positivity/positivities of any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Ccl7, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3ga16, Slc39a12, Tacr1, Lrtm1 and Dscam, and/or the negativity of CD201. ### Claim 8 (depends on 7) The method according to claim 7, wherein the positive marker is Lrtm1. ### Claim 9 (depends on 7) The method according to claim 7, wherein said step further comprise detecting dopaminergic neuron progenitor cells by using as an index/indices the positivity/positivities of corin and/or Lmx1a. ### Claim 10 (depends on 7) The method according to claim 7, wherein said dopaminergic neuron progenitor cells are human dopaminergic neuron progenitor cells. ### Claim 11 (depends on 7) The method according to claim 7, wherein said cell population comprising dopaminergic neuron progenitor cells is a cell population whose differentiation is induced from pluripotent stem cells, or a cell population composed of cells of an isolated tissue(s). ### Claim 12 (depends on 11) The method according to claim 11, wherein said cell population whose differentiation is induced from pluripotent stem cells is a cell population obtained by culturing pluripotent stem cells in a medium supplemented with a BMP inhibitor and a TGFβ inhibitor. ### Claim 13 A kit for detecting dopaminergic neuron progenitor cells, comprising a reagent(s) for detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Ccl7, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3ga16, Slc39a12, Tacr1, Lrtm1, Dscam and CD201. ### Claim 14 (depends on 13) The kit according to claim 13, wherein said reagent(s) is/are an antibody/antibodies. ### Claim 15 (depends on 14) The kit according to claim 14, wherein the antibody is anti-Lrtm1 antibody which recognized an extracellular domain of Lrtm1. ### Claim 16 (depends on 1) A therapeutic agent for Parkinson's disease, comprising dopaminergic neuron progenitor cells produced by the method according to claim 1.